Yehuda Handelsman, MD

Welcome to the 18th WCIRDC Slides

Robert Chilton, DO

The Myocardium: Too Fat to be Fit

Ralph DeFronzo, MD

Fatty Kidney: The Renal Manifestation of the Metabolic Syndrome

Kenneth Cusi, MD

Nonalcoholic Fatty Liver Disease and Diabetes: Clinical Implications of "Foie Gras"

Eric Ravussin, PhD

The Beta Cell- Insulin Resistance Connection: A Fat Story

Martha Gulati, MD

Sex Differences in Coronary Artery Calcium and Long-Term CV Mortality

Gina P. Lundberg, MD

Sex-Specific Differences in Risk Factors for Development of Heart Failure in Women

Howard Hodis, MD

Hormone Replacement Therapy, Atherosclerosis and Cardiovascular Disease: An Update

Paul Zimmet, AO, MD, PhD

Two Pandemics in Collision: COVID-19 and Diabetes

Stefan Bornstein, MD

Managing Patients with Diabetes and COVID-19

Geltrude Mingrone,MD

Obesity and Metabolic Surgery During and Beyond COVID-19

Derek LeRoith, MD, PhD

Overview of The Interaction Between Obesity, Diabetes and Cancer Therapy

Emily Gallagher, MD, PhD

The Effect of Tyrosine Kinase, PI3K/mTor Inhibitors on Metabolism

Kevan Herold, MD

Immunobiologics Effect on Diabetes: Type 1 And Type 2

Richard Bergman, PhD

Important Role of Reduced Insulin Clearance in Pathogenesis of Type 2 Diabetes: Hypothesis and Experimental Confirmation in Man

Maria Rosa Costanzo, MD

Epidemiology and Traditional Management of HF and CKD

Mikhail Kosiborod, MD

The Future Is Here: Contemporary Approach to HF with a Focus on HFrEF

Katherine Tuttle, MD

Revolution in the Management of Moderate to Severe CKD

Muthiah Vaduganathan, MD

Impact of Recent CVOTs on Contemporary Guidelines for HF and CKD

Aaron Kelly, PhD

The Ceramide Pathway as a Target for Insulin Sensitization

Thomas Inge, MD, PhD

Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults

Sonia Caprio, MD

Sleeve Gastrectomy Impact on Cell Size and Genes from Adipose Tissue of Obese Adolescent Girls

Philipp Scherer, PhD

The Ceramide Pathway as a Target for Insulin Sensitization

Gerald Shulman, MD, PhD

Diacylglycerols and acetyl-CoA as a Therapeutic Targets for Insulin Resistance and Type 2 Diabetes

Kausik Ray, MD

New Agents: PCSK9 siRNA (inclisiran) and Bempedoic Acid

Robert Rosenson, MD

Triglycerides and CVD: Causal or Coincidental? Lessons from Recent Research

Norman Lepor, MD

The Role of LP(a) & ANGPTL3 in Lipids Atherosclerosis and Cardiovascular Disease

Jay Skyler, MD

Islet Cell Preservation & Replacement

Ronald Evans, PhD

Stem Cell Generated Human Islets- Rescue Diabetes Without a Device

George Grunberger, MD

State of the Art Insulin Delivery Systems

Julio Rosenstock, MD

Tomorrow’s New Insulin Today

James Sowers, MD

Insulin Resistance and Cardiovascular Disease

Dimitri Mikhailidis, MD

Insulin resistance, NAFLD/NASH and CVD Risk

Gerald Watts, MD

Go with the Flow: Understanding Lipid Metabolism with Tracer Methods

Michael Snyder, PhD

Multiomics Analysis of IR vs IS Responses to Viral Infections, Exercise and Aging

Tracey McLaughlin, MD

Continuous Glucose Monitoring for Precision Diets

Jerome Rotter, MD

The Genetic Interrelationship Between T2D & Coronary Heart Disease

Christos Mantzoros, MD, PhD

NASH- The Status of Diagnostics and Therapeutics

Bart Staels, PhD

The Sexually Dimorphic Nature of NASH May Impact on Disease Progression and Responses To Drugs

Jorge Plutzky, MD

Anti-Inflammatory Impact on Atherosclerosis: CVOT and Management Implications

Matthew Budoff, MD

Impact of Non Statin Drugs On Plaque Formation and Atherosclerosis

Peter Reaven, MD

GLP1ra and Atherosclerosis- Human Data at Last

Kevin Hall, PhD

The Influence of Dietary Carbs, Fat, And Quality on Ad Libitum Calorie Intake

W. Timothy Garvey, MD

Future of Obesity Pharmacotherapy: New Drugs and New Targets

Philip Schauer, MD

Effects of Bariatric Surgery on Cardiovascular Events

Samuel Klein, MD

Does Intestinal Bypass Surgery Really Have Weight-Loss-Independent Therapeutic Metabolic Effects?

Peter A. McCullough, MD

Pathophysiological Basis & Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

Erin D. Michos, MD

Sex Differences in Mortality from COVID-19 Pandemic

Ajay Nirula, MD, PhD

The Role of Neutralizing Antibody Therapy in the Management of COVID-19

Tracey McLaughlin, MD

Obesity & COVID-19

Deepak Bhatt, MD

Primary and Secondary Prevention of CVD – Current standard of Care

Neha Pagidipati, MD

High TGL association with ASCVD- Epidemiology and pathophysiology

Matthew Budoff, MD

IPE impact on ASCVD Morbidity and Mortality

Yehuda Handelsman, MD

Lipid Guidelines IPE related

Peter Grant, MD

Insulin Resistance And Thrombotic Risk: Implications For Therapeutic Approaches To Vascular Disease

Sanjay Kaul, MD

Update of Recent CV Outcome Trials

Brendan Everett, MD

The ACC’s Expert Consensus Decision Pathway: Improving Cardiovascular Outcomes in Type 2 Diabetes

Mikhail N. Kosiborod, MD

The Future of Cardiometabolic Care is Here: Announcing Cardiometabolic Center Alliance

Francesco Giorgino, MD

Managing Type 2 Diabetes to Prevent CVD-CKD: SGLT-2i, GLP-1RA or Initial Combination of Both?

Vivian Fonseca, MD

Hypoglycemia Impact and Management

Richard Bergenstal, MD

The Role of CGM in Diabetes Update toward 2021

Robert Eckel, MD

The Current Management of CV Risk factors in Type 1 Diabetes

Richard Pratley, MD

DEBATE: Should T2D Medications with Proven CV Benefits be Used in T1D to Prevent ASCVD: Yes

David Nathan, MD

Why Using T2D Medications with CVD Benefits is a Bad Idea for Type 1 Diabetes

Matthew Weir, MD

KDIGO- Diabetes CKD and Hypertension New Guidelines

David Cherney, MD

GLP1-RA and SGLT2i in the Treatment of Diabetic Nephropathy: What Does the Future Hold?

Monica Aggarwal, MD

Lifestyle Modifications for Preventing and Treating Heart Failure

Carolyn Lam Su Ping, PhD

All We Need to Know about HFpeF

Javed Butler, MD

Update on HFOT impact on Management - Sequencing vs Initial Combination of Medication